Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy

Immune checkpoint inhibitor (ICI) responses vary, and biomarkers for predicting responders are urgently needed. Growing evidence points to the association between programmed cell death protein ligand 2 (PDL2) and ICI benefits, while clinical evidences were lacking. Thus, we consolidated five public...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aoyun Wang, Han Chu, Zheng Jin, Qingzhu Jia, Bo Zhu
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/f0bf6ee740784952adeb3b540009e7c6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f0bf6ee740784952adeb3b540009e7c6
record_format	dspace
spelling	oai:doaj.org-article:f0bf6ee740784952adeb3b540009e7c62021-11-08T02:36:42ZProgrammed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy1875-863010.1155/2021/9453692https://doaj.org/article/f0bf6ee740784952adeb3b540009e7c62021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/9453692https://doaj.org/toc/1875-8630Immune checkpoint inhibitor (ICI) responses vary, and biomarkers for predicting responders are urgently needed. Growing evidence points to the association between programmed cell death protein ligand 2 (PDL2) and ICI benefits, while clinical evidences were lacking. Thus, we consolidated five public ICI-treated cohorts to investigate the association between PDL2 expression and ICI treatment prognosis. Immune cell signatures and IFN-γ signatures are investigated in The Cancer Genome Atlas (TCGA) dataset and later in ICI-treated cohorts to explore the association between PDL2 and antitumor immunity in the tumor microenvironment (TME). We found that immune cell signatures and IFN-γ signatures were enriched in the PDL2-high group in TCGA pooled cohorts and most cancers. Consistently, in ICI-treated cohorts, patients with high PDL2 expression experienced longer overall survival time (OS) and were more likely responsive to ICIs than patients with low PDL2 expression. Immune cell scores of the high PDL2 expression patients were significantly higher (P<0.05) than those of the low PDL2 expression patients in ICI-treated cohorts. In conclusion, our findings suggest that PDL2 is a potential predictive biomarker for ICIs.Aoyun WangHan ChuZheng JinQingzhu JiaBo ZhuHindawi LimitedarticleMedicine (General)R5-920ENDisease Markers, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Aoyun Wang Han Chu Zheng Jin Qingzhu Jia Bo Zhu Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy
description	Immune checkpoint inhibitor (ICI) responses vary, and biomarkers for predicting responders are urgently needed. Growing evidence points to the association between programmed cell death protein ligand 2 (PDL2) and ICI benefits, while clinical evidences were lacking. Thus, we consolidated five public ICI-treated cohorts to investigate the association between PDL2 expression and ICI treatment prognosis. Immune cell signatures and IFN-γ signatures are investigated in The Cancer Genome Atlas (TCGA) dataset and later in ICI-treated cohorts to explore the association between PDL2 and antitumor immunity in the tumor microenvironment (TME). We found that immune cell signatures and IFN-γ signatures were enriched in the PDL2-high group in TCGA pooled cohorts and most cancers. Consistently, in ICI-treated cohorts, patients with high PDL2 expression experienced longer overall survival time (OS) and were more likely responsive to ICIs than patients with low PDL2 expression. Immune cell scores of the high PDL2 expression patients were significantly higher (P<0.05) than those of the low PDL2 expression patients in ICI-treated cohorts. In conclusion, our findings suggest that PDL2 is a potential predictive biomarker for ICIs.
format	article
author	Aoyun Wang Han Chu Zheng Jin Qingzhu Jia Bo Zhu
author_facet	Aoyun Wang Han Chu Zheng Jin Qingzhu Jia Bo Zhu
author_sort	Aoyun Wang
title	Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy
title_short	Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy
title_full	Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy
title_fullStr	Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy
title_full_unstemmed	Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy
title_sort	programmed cell death protein ligand 2 is a potential biomarker that predicts the efficacy of immunotherapy
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/f0bf6ee740784952adeb3b540009e7c6
work_keys_str_mv	AT aoyunwang programmedcelldeathproteinligand2isapotentialbiomarkerthatpredictstheefficacyofimmunotherapy AT hanchu programmedcelldeathproteinligand2isapotentialbiomarkerthatpredictstheefficacyofimmunotherapy AT zhengjin programmedcelldeathproteinligand2isapotentialbiomarkerthatpredictstheefficacyofimmunotherapy AT qingzhujia programmedcelldeathproteinligand2isapotentialbiomarkerthatpredictstheefficacyofimmunotherapy AT bozhu programmedcelldeathproteinligand2isapotentialbiomarkerthatpredictstheefficacyofimmunotherapy
_version_	1718443149663141888

Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy

Ejemplares similares